We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (TheraP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03392428
Recruitment Status : Completed
First Posted : January 8, 2018
Last Update Posted : June 13, 2022
Sponsor:
Collaborators:
Australian Nuclear Science and Technology Organisation (ANSTO)
Endocyte
Prostate Cancer Foundation of Australia (PCFA)
Australasian Radiopharmaceutical Trials network (ARTnet)
Movember Foundation
Information provided by (Responsible Party):
Australian and New Zealand Urogenital and Prostate Cancer Trials Group

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
Recruitment Status : Completed
Actual Primary Completion Date : December 31, 2019
Actual Study Completion Date : December 31, 2021
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):